The drug, known as Neurelan, has been shown to reverse tetrodotoxin toxicity in animal experiments.
4-Aminopyridine is marketed as an avicide under the trade name Avitrol. In this treatment it causes convulsions and rarely death, depending on dosage.
4-AP works as a potassium channel blocker. Electrophysiologic studies of demyelinated axons show that abnormal potassium currents decrease action potential duration and amplitude and contribute to conduction failure. Potassium channel blockade prolongs the depolarization phase of the action potential, increasing conductivity along the demyelinated axon.
MS patients treated with 4-AP exhibited a response rate of 29.5% to 80%. A long-term study (32 months) indicated that 80-90% of patients who initially responded to 4-AP exhibited long-term benefits. Although improving symptoms, 4-AP does not inhibit progression of MS.
Spinal cord injury patients have also seen improvement with 4-AP therapy. These improvements include sensory, motor and pulmonary function, with a decrease in spasticity and pain..
WIPO ASSIGNS PATENT TO HENKEL FOR "4-AMINOPYRIDINE DERIVATIVES AS CATALYSTS FOR THE CLEAVAGE OF ORGANIC ESTERS" (GERMAN INVENTORS)
Sep 24, 2010; GENEVA, Sept. 24 -- Publication No. WO/2010/105942 was published on Sept. 23. Title of the invention: "4-aminopyridine...
US Patent Issued to L'Oreal on July 23 for "Cationic 4-Aminopyridine, Dye Composition Comprising a Cationic 4-Aminopyridine, Processes Therefor and Uses Thereof" (French Inventor)
Jul 23, 2013; ALEXANDRIA, Va., July 23 -- United States Patent no. 8,491,669, issued on July 23, was assigned to L'Oreal (ParisCationic...
US Patent Issued on Feb. 8 for "4-Aminopyridine and a Pharmaceutical Composition for Treatment of Neuronal Disorders" (Alabama Inventor)
Feb 12, 2011; ALEXANDRIA, Va., Feb. 12 -- United States Patent no. 7,884,079, issued on Feb. 8. "4-aminopyridine and a Pharmaceutical...